Bonade tablets 2 + 0.03mg, # 21

contraception (prevention of unwanted pregnancy);

treatment of mild to moderate acne in women who need contraception, with the ineffectiveness of other treatments (topical treatment or the use of systemic antibiotics).

When and how to take BONADEЃ

BONADEЃ is taken orally, one tablet a day, without chewing and drinking a small amount of water, at the same time every day. The tablets are taken within 21 days without interruption according to the scheme indicated on the blister. Each blister contains 21 tablets. Each tablet is labeled with the day of the week on which it should be taken. For the next 7 days, the tablets are not taken. Menstrual bleeding (withdrawal bleeding) should begin during this period. It usually starts 2-3 days after the last BONADEЃ tablet has been taken.

After a 7-day break, on the 8th day, start taking pills from a new package (if the package contains 21 tablets) or a blister (if the package contains 63 tablets), even if the bleeding has not stopped yet. This means that the patient will always start a new blister pack on the same day of the week and withdrawal bleeding will occur on approximately the same day every month.

How to start taking BONADEЃ

In the absence of taking any hormonal contraceptives in the previous month. Taking BONADEЃ is started on the first day of the natural menstrual cycle (i.e. on the first day of menstrual bleeding). Take the pill marked on the appropriate day of the week. For example, if your period starts on Friday, take a pill marked with the letters for Friday. Then they continue to take the pills on the following days in the prescribed manner. It is also permissible to start taking from the 2nd to the 5th day of the cycle, but in this case it is recommended to additionally use a barrier method of contraception (condom) during the first 7 days of taking the tablets from the first package (blister).

When switching from other COCs, a contraceptive vaginal ring or a contraceptive patch. You can start taking BONADEЃ the next day after taking the last tablet from the previous COC package (i.e. without interruption). If the previous package also contained inactive tablets (without active substance), you can start using BONADEЃ the next day after taking the last active tablet. You can also start taking it later, but in no case later than the next day, after the usual break in taking (a break of 7 days for drugs containing 21 tablets) or after taking the last inactive tablet (for drugs containing 28 tablets in a package) ...

If you use a contraceptive patch or a contraceptive vaginal ring, you should start taking BONADEЃ on the day they are removed, but no later than the day when a new ring is to be inserted or a new patch is glued on.

When switching from oral contraceptives containing only progestogen (mini-pills). The patient can stop taking mini-pills any day and start taking BONADEЃ the next day at the same time. During the first 7 days of taking the pills, you must also use an additional barrier method of contraception.

When switching from an injectable contraceptive, an implant, or an intrauterine contraceptive (intrauterine device) that releases a progestogen. Start taking BONADEЃ on the day the next injection is to be made or on the day the implant or intrauterine contraceptive is removed. During the first 7 days of taking the pills, you must also use an additional barrier method of contraception.

After childbirth. Immediately after the baby is born, the doctor may recommend that the patient wait until the end of the first normal menstrual cycle before taking BONADEЃ. Sometimes, on the recommendation of a doctor, you can start taking the drug earlier.

After a spontaneous miscarriage or abortion in the first trimester of pregnancy. It is necessary to consult a doctor. It is usually recommended to start taking the drug immediately.

If you miss taking BONADEЃ.

If the delay in taking the next pill is less than 12 hours, the contraceptive effect of BONADEЃ remains. The pill should be taken as soon as the patient remembers it. Take the next pill at the usual time.

If the delay in taking the pills is more than 12 hours, contraceptive protection may be reduced. The more tablets are missed in a row and the closer this pass is to the beginning of the intake or to the end of the intake, the higher the risk of pregnancy.

In this regard, you can be guided by the following rules:

- more than 1 table is missing. from packaging (blister). It is necessary to consult a doctor;

- 1 table is omitted. in the 1st week of taking the drug. Take the missed tablet as soon as possible, as soon as the patient remembers (even if it means taking 2 tablets at the same time). Take the next pill at the usual time. Additionally, use a barrier method of contraception for the next 7 days. If intercourse was within a week before the pill was missed, the likelihood of pregnancy must be taken into account. Seek medical advice immediately;

- one tablet was missed in the 2nd week of taking the drug. Take the missed tablet as soon as possible, as soon as the patient remembers (even if it means taking 2 tablets at the same time). Take the next pill at the usual time. If the patient took the pills correctly within 7 days preceding the first missed pill, the contraceptive effect of BONADEЃ is preserved and the woman does not need to use additional contraceptive measures. Otherwise, as well as when skipping two or more pills, it is necessary to additionally use barrier methods of contraception for 7 days.

- one tablet was missed on the 3rd week of taking the drug. If during the 7 days preceding the first missed pill, all pills were taken correctly, there is no need to use additional contraceptive methods if the patient adheres to either of the following two options.

1. Take the missed tablet as soon as possible, as soon as the woman remembers (even if it means taking 2 tablets at the same time). Take the next pill at the usual time. Start the next pack (blister) immediately after the end of taking the tablets from the current pack (blister), so there will be no break between packs (blisters). Withdrawal bleeding is unlikely until the pills from the 2nd package (blister) run out, but spotting or breakthrough uterine bleeding may occur on the days of taking the drug.

2. Stop taking pills from the current package (blister), take a break for 7 days or less (including the day the pill was skipped) and then start taking the pills from the new package (blister). If there is no expected menstrual bleeding after taking a pill, the woman may be pregnant. You should consult your doctor before you start taking pills from a new package (blister).

In situations where a woman is advised to stop taking BONADEЃ, or its reliability may be reduced, abstain from sexual intercourse or use non-hormonal contraceptive methods (for example, a condom or other barrier methods). Rhythmic or temperature methods should not be used. These methods can be unreliable because taking COCs leads to changes in basal temperature and cervical mucus.

If you stop taking BONADEЃ

You can stop taking BONADEЃ at any time. In case of discontinuation due to a desire to become pregnant, it is usually recommended to wait for the first normal menstruation and only then try to become pregnant. This method makes it easier to establish the due date.

Recommendations for gastrointestinal disorders

In the event of vomiting or diarrhea, the active ingredients of BONADEЃ may not be completely absorbed. If vomiting continues 3-4 hours after taking the contraceptive pill, the result may be the same as if you skip taking the pill. You should act as recommended in case of missing a pill. In case of severe diarrhea, you should consult your doctor.

Delaying the onset of menstrual bleeding

You can delay the onset of menstrual bleeding if you start taking pills from the next package (if the package contains 21 tablets) or blisters (if the package contains 63 tablets) immediately after the end of the current package (blister). You can take the tablets as long as the woman wishes, or until the tablets in the package (blister) run out. If it is necessary for withdrawal bleeding to begin, you should simply stop taking the pills. While taking BONADEЃ tablets from a new package (blister), profuse or spotting bleeding may appear. Start taking the tablets from the next package (blister) after the usual 7-day interval.

Change in day of onset of menstrual bleeding

If a woman takes pills, strictly following all the recommendations, menstrual bleeding occurs on about the same days every 4 weeks. If you need to change these days, you just need to shorten (but in no case prolong) the next interval without taking pills. For example, bleeding starts on Fridays, but it is necessary that it starts on Tuesdays (3 days earlier), then you need to start taking pills from a new package (blister) 3 days earlier than usual. If the pill-free interval is too short, bleeding may not occur at all during that interval. However, while taking pills from a new package (blister), profuse or spotting spotting may appear.

Additional information for specific patient groups

Children and adolescents. BONADEЃ is indicated only after the onset of menarche.

Elderly patients. Not applicable. BONADEЃ is not indicated after menopause.

Patients with impaired liver function. BONADEЃ is contraindicated in women with severe liver disease until the liver function tests return to normal (see also 'Contraindications').

Patients with impaired renal function. The use of BONADEЃ has not been specifically studied in patients with impaired renal function. The available data do not suggest a change in the dosage regimen in these patients.

BONADEЃ should not be used in the presence of any of the conditions / diseases listed below. If any of these conditions develops for the first time while taking it, the drug should be stopped immediately.

hypersensitivity to any component of BONADEЃ;

thrombosis (venous and arterial) and thromboembolism currently or in history (including deep vein thrombosis, pulmonary embolism, myocardial infarction);

conditions preceding thrombosis (including angina pectoris) at the present time or in anamnesis;

cerebrovascular disease: stroke, transient ischemic attacks at present and in history;

multiple or severe risk factors for venous or arterial thrombosis, incl. complicated lesions of the valve apparatus of the heart, atrial fibrillation, diseases of the vessels of the brain or coronary arteries of the heart, severe dyslipoproteinemia, uncontrolled arterial hypertension, serious surgery, prolonged immobilization, surgery on the lower extremities and pelvic organs, neurosurgical interventions, smoking over the age of 35 years;

congenital or acquired predisposition to arterial or venous thrombosis (resistance to activated protein C (including Leiden factor 5), antithrombin III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia, antibodies to phospholipids (anticardiolipin, lupus); anticoagulant

migraine with focal neurological symptoms at present or in history;

diabetes mellitus with vascular complications;

pancreatitis with severe hypertriglyceridemia at present or in history;

liver failure and severe liver disease (before normalization of liver enzymes), incl. Rotor and Dubin-Johnson syndromes;

liver tumors (benign or malignant), current or history;

identified hormone-dependent malignant neoplasms (including genitals or mammary glands) or suspicion of them;

vaginal bleeding of unknown origin;

pregnancy or suspicion of it;

breastfeeding period;

intolerance to galactose, lactase deficiency or glucose-galactose malabsorption (the drug contains lactose);

obesity (body mass index over 30 kg / m2);

extensive trauma;

BONADEЃ is not intended for use in men.

With caution: the potential risk and expected benefit of using COCs in each individual case should be carefully weighed in the presence of the following diseases / conditions and risk factors.

risk factors for thrombosis and thromboembolism: smoking; obesity (body mass index over 30 kg / m2); dyslipoproteinemia, arterial hypertension; migraine without focal neurological symptoms; uncomplicated valvular heart disease; hereditary predisposition to thrombosis (thrombosis, myocardial infarction or cerebrovascular accident at a young age in one of the closest relatives);

other diseases in which peripheral circulatory disorders may occur: diabetes mellitus; cancer, systemic lupus erythematosus; hemolytic uremic syndrome; Crohn's disease and ulcerative colitis; sickle cell anemia; phlebitis of superficial veins;

hereditary angioedema;

hypertriglyceridemia;

diseases that first appeared or worsened during pregnancy or against the background of previous use of sex hormones (for example, jaundice, cholestasis, gallbladder disease, otosclerosis with hearing impairment, porphyria, herpes during pregnancy, Sydenham's chorea);

postpartum period.